Appendix cancer, once rare, is now rising sharply among younger adults. Firstpost brings out an expert’s views on the risk ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

BE is the only known precursor to esophageal cancer. The condition is caused by prolonged exposure of the esophagus to ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent ...

Hepatocellular carcinoma (HCC), the most common type of liver cancer and the third-leading cause of cancer-related deaths ...

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...

Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Gastrointestinal cancer is rising sharply among Gen X and Millennials, prompting experts to call for more research.. Credit: Annie Cavanagh / CC BY-NC 4.0. A rare form of gastrointestinal cancer is ...